Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma

Haematologica Reports

Volumn 2, Issue 13, 2006, Pages 38-39

  Querfeld, C ^a   Kuzel, T M ^a   Guitart, J ^a   Rosen, S T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; STEROID; THALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANEMIA; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TRANSFUSION; BURKITT LYMPHOMA; CANCER PATIENT; CELL MEDIATED CYTOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CUTANEOUS T CELL LYMPHOMA; CYTOPENIA; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FOOD; FOOD DRUG INTERACTION; GENE DELETION; HUMAN; LEG EDEMA; LYMPHADENOPATHY; MALAISE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRURITUS; RASH; RECOMMENDED DRUG DOSE; SEZARY CELL; SKIN BURNING SENSATION; SKIN DISEASE; SLURRED SPEECH; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 46849108946     PISSN: 18249337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Natl Rev Cancer 2004;4:314-22.
2. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl JMed 2005;352:549-57.
3. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7.
4. Maier SK,Hammond JM. Role of lenalidomide in the treatment of multiply myeloma and myelodysplastic syndrome. Annals Pharm 2006;40:286-9.